Peptide Based Cancer Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Aug-2017 | List of Tables : 150 | List of Figures : 48 | No. of Pages : 170 | Report Code : FACT179MR |

Peptide based cancer therapeutics are yet to become widespread, but the initial low numbers certainly do not suggest any pessimism in the global market. With new developments in delivery, stability, modifications, and preclinical success, future growth potentials of such cancer therapeutics continue to intensify.  A slew of new peptides with positive preclinical results are entering into clinical trials that are focused on cancer treatment. Moreover, the application base of peptides is steadily expanding to other therapeutic areas as well. In the near future, the global peptide based cancer therapeutics market is likely to be influenced by the rising prevalence of cancer across the globe. WHO reveals that cancer is one of the leading causes of death worldwide, which accounted for more than 8 million deaths in 2015. Factor as such are expected to play an important role in boosting the popularity of peptide based cancer therapeutics further. In addition, various complications involved in conventional cancer therapeutics as well as the risk of sever side-effects are prompting medical professionals to utilise peptides in tumor and cancer treatment. Fact.MR’s latest report projects that the global peptide based cancer therapeutics market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2% during the forecast period (2017-2022).

Peptide is a compound that is created by artificial or natural biological chaining of amino acid monomers. In recent years, peptides have emerged as an effective therapeutic agent in treatment of various diseases, including cancer. At present, there are a number of peptide based cancer therapeutics available in the market.  Incessant medical research on peptides has led to development of several peptide based cancer therapeutics that are showing greater results as compared to conventional cancer therapeutics.

Market Taxonomy

Drug

Distribution Channel

Goserelin

Hospital Pharmacies

Bortezomib

Retail Pharmacies

leuprorelin

Online Pharmacies

Others

 

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

North America To Lead The Global Peptide Based Cancer Therapeutics Market

In terms of revenues, North America is expected to dominate the global peptide based cancer therapeutics market in 2017 and beyond. The region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. During the forecast period, the market in the region is expected to surge at a robust CAGR.

On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.

Competition Tracking

Fact.MR’s report has also profiled key companies that are operating in the global peptide based cancer Therapeutic market, which include AstraZeneca PLC, Allergan plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Abbott, AbbVie Inc., and Valeant Pharmaceuticals International, Inc.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Medical research institutes as well as investors in the global pharmaceuticals sector are ramping up their efforts toward development of profound therapeutic drugs for treating cancer. This Fact.MR report analyzes the expansion of global peptide based cancer therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.

Scope

The scope of Fact.MR’s report is to analyze the global peptide based cancer therapeutics market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Drug manufacturers, research institutes, and raw material suppliers in the global peptide based cancer therapeutics market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide based cancer therapeutics.  

Summary

The report commences with a brief information of the global peptide based cancer therapeutics market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide based cancer therapeutics market. 

Overview

The next section offers an overview of the global peptide based cancer therapeutics market. This comprises an introduction to the market, along with a standard definition of the product – peptide based cancer therapeutics. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period. 

The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.

In order to offer readers with up-to-date information about the latest advancements in the global peptide based cancer therapeutics market, the report provides updates about market opportunities, which can benefit leading manufacturers of peptide based cancer therapeutic drugs. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for peptide based cancer therapeutic drug manufacturers to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section.

The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide based cancer therapeutics market. Drug, distribution channel and region are key segments that define the growth of the global market for peptide based cancer therapeutics. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included. 

The report’s last section comprises of the global peptide based cancer therapeutics market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide based cancer therapeutics market.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

1. Global Peptide Based Cancer Therapeutics Market - Executive Summary

2. Global Peptide Based Cancer Therapeutics Market Overview
2.1. Introduction
       2.1.1. Global Peptide Based Cancer Therapeutics Market Taxonomy
       2.1.2. Global Peptide Based Cancer Therapeutics Market Definition
2.2. Global Peptide Based Cancer Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
       2.2.1. Global Peptide Based Cancer Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Cancer Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis 
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Peptide Based Cancer Therapeutics Market Analysis and Forecast By Drug 
3.1. Global Peptide Based Cancer Therapeutics Market Size and Forecast By Drug, 2012-2022
       3.1.1. Goserelin Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                3.1.1.2. Market Share Comparison, By Region
                3.1.1.3. Y-o-Y growth Comparison, By Region
       3.1.2. Bortezomib Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                3.1.2.2. Market Share Comparison, By Region
                3.1.2.3. Y-o-Y growth Comparison, By Region
       3.1.3. leuprorelin Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region
                3.1.3.2. Market Share Comparison, By Region
                3.1.3.3. Y-o-Y growth Comparison, By Region
       3.1.4. Others Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                3.1.4.1. Revenue (US$ Mn) Comparison, By Region
                3.1.4.2. Market Share Comparison, By Region
                3.1.4.3. Y-o-Y growth Comparison, By Region

4. Global Peptide Based Cancer Therapeutics Market Analysis and Forecast By Distribution Channel 
4.1. Global Peptide Based Cancer Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
       4.1.1. Hospital Pharmacies Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Retail Pharmacies Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                4.1.2.2. Market Share Comparison, By Region
                4.1.2.3. Y-o-Y growth Comparison, By Region
       4.1.3. Online Pharmacies Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                4.1.3.2. Market Share Comparison, By Region
                4.1.3.3. Y-o-Y growth Comparison, By Region

5. Global Peptide Based Cancer Therapeutics Market Analysis and Forecast By Region
5.1. Global Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       5.1.1. North America Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                5.1.1.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.2. Latin America Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                5.1.2.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.3. Europe Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                5.1.3.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.4. Japan Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                5.1.4.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.5. APEJ Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                5.1.5.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.6. MEA Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
                5.1.6.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

6. North America Peptide Based Cancer Therapeutics Market Analysis and Forecast, By Country, 2012-2022
6.1. US Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       6.1.1. Revenue (US$ Mn) Comparison, By Drug 
       6.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
6.2. Canada Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       6.2.1. Revenue (US$ Mn) Comparison, By Drug 
       6.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

7. Latin America Peptide Based Cancer Therapeutics Market Analysis and Forecast, By Country, 2012-2022
7.1. Brazil Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       7.1.1. Revenue (US$ Mn) Comparison, By Drug 
       7.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.2. Mexico Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       7.2.1. Revenue (US$ Mn) Comparison, By Drug 
       7.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.3. Argentina Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       7.3.1. Revenue (US$ Mn) Comparison, By Drug 
       7.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

8. Europe Peptide Based Cancer Therapeutics Market Analysis and Forecast, By Country, 2012-2022
8.1. Germany Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       8.1.1. Revenue (US$ Mn) Comparison, By Drug 
       8.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.2. UK Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       8.2.1. Revenue (US$ Mn) Comparison, By Drug 
       8.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.3. France Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       8.3.1. Revenue (US$ Mn) Comparison, By Drug 
       8.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.4. Spain Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       8.4.1. Revenue (US$ Mn) Comparison, By Drug 
       8.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.5. Italy Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       8.5.1. Revenue (US$ Mn) Comparison, By Drug 
       8.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.6. Nordic Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       8.6.1. Revenue (US$ Mn) Comparison, By Drug 
       8.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

9. Japan Peptide Based Cancer Therapeutics Market Analysis and Forecast, By Country, 2012-2022
9.1. Japan  Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       9.1.1. Revenue (US$ Mn) Comparison, By Drug 
       9.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

10. APEJ Peptide Based Cancer Therapeutics Market Analysis and Forecast, By Country, 2012-2022
10.1. China Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       10.1.1. Revenue (US$ Mn) Comparison, By Drug 
       10.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.2. India Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       10.2.1. Revenue (US$ Mn) Comparison, By Drug 
       10.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.3. Malaysia Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       10.3.1. Revenue (US$ Mn) Comparison, By Drug 
       10.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.4. Thailand Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       10.4.1. Revenue (US$ Mn) Comparison, By Drug 
       10.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.5. Singapore Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       10.5.1. Revenue (US$ Mn) Comparison, By Drug 
       10.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.6. Australia Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       10.6.1. Revenue (US$ Mn) Comparison, By Drug 
       10.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

11. MEA Peptide Based Cancer Therapeutics Market Analysis and Forecast, By Country, 2012-2022
11.1. GCC Countries Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       11.1.1. Revenue (US$ Mn) Comparison, By Drug 
       11.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.2. South Africa Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       11.2.1. Revenue (US$ Mn) Comparison, By Drug 
       11.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.3. Nigeria Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       11.3.1. Revenue (US$ Mn) Comparison, By Drug 
       11.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.4. Israel Peptide Based Cancer Therapeutics Market Size and Forecast, 2012-2022
       11.4.1. Revenue (US$ Mn) Comparison, By Drug 
       11.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

12. Global Peptide Based Cancer Therapeutics Market Competition Landscape and Company Profile
12.1. Company Share Analysis By Region
12.2. AstraZeneca plc
       12.2.1. Company Overview
       12.2.2. Peptide Based Cancer Therapeutics Market Drug list
       12.2.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.2.4. Key Developments
       12.2.5. SWOT Analysis
12.3. Allergan plc
       12.3.1. Company Overview
       12.3.2. Peptide Based Cancer Therapeutics Market Drug list
       12.3.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.3.4. Key Developments
       12.3.5. SWOT Analysis
12.4. Pfizer Inc
       12.4.1. Company Overview
       12.4.2. Peptide Based Cancer Therapeutics Market Drug list
       12.4.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.4.4. Key Developments
       12.4.5. SWOT Analysis
12.5. Takeda Pharmaceutical Company Limited
       12.5.1. Company Overview
       12.5.2. Peptide Based Cancer Therapeutics Market Drug list
       12.5.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.5.4. Key Developments
       12.5.5. SWOT Analysis
12.6. Johnson & Johnson
       12.6.1. Company Overview
       12.6.2. Peptide Based Cancer Therapeutics Market Drug list
       12.6.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.6.4. Key Developments
       12.6.5. SWOT Analysis
12.7. Abbott
       12.7.1. Company Overview
       12.7.2. Peptide Based Cancer Therapeutics Market Drug list
       12.7.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.7.4. Key Developments
       12.7.5. SWOT Analysis
12.8. AbbVie Inc
       12.8.1. Company Overview
       12.8.2. Peptide Based Cancer Therapeutics Market Drug list
       12.8.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.8.4. Key Developments
       12.8.5. SWOT Analysis
12.9. Valeant Pharmaceuticals International, Inc
       12.9.1. Company Overview
       12.9.2. Peptide Based Cancer Therapeutics Market Drug list
       12.9.3. Peptide Based Cancer Therapeutics Market Drug Sales Data and Key Financials
       12.9.4. Key Developments
       12.9.5. SWOT Analysis

13. Research Methodology

14. Secondary and Primary Sources

15. Assumptions and Acronyms

16. Disclaimer

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Peptide Based Cancer Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022